FY2027 Earnings Forecast for TMO Issued By Erste Group Bank

Thermo Fisher Scientific Inc. (NYSE:TMO) – Analysts at Erste Group Bank upped their FY2027 earnings estimates for shares of Thermo Fisher Scientific in a research report issued to clients and investors on Thursday, October 8th. Erste Group Bank analyst H. Engel now expects that the medical research company will post earnings per share of $27.51 for the year, up from their prior estimate of $27.44. The consensus estimate for Thermo Fisher Scientific’s current full-year earnings is $25.13 per share.

A number of other research analysts have also recently weighed in on TMO. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $720.00 target price on shares of Thermo Fisher Scientific in a research note on Friday, September 25th. CLSA initiated coverage on Thermo Fisher Scientific in a research note on Thursday, September 3rd. They issued an “outperform” rating and a C$748.00 price target for the company. BMO Capital Markets cut Thermo Fisher Scientific to a “market perform” rating in a report on Wednesday, September 9th. Wall Street Zen upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, October 3rd. Finally, HSBC raised Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 1st. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and an average target price of $638.67.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO opened at $661.65 on Tuesday. The stock has a market cap of $244.64 billion, a PE ratio of 35.59, a price-to-earnings-growth ratio of 2.75 and a beta of 0.87. Thermo Fisher Scientific has a 1 year low of $435.27 and a 1 year high of $694.33. The firm has a fifty day moving average price of $629.14 and a 200-day moving average price of $543.01. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating the consensus estimate of $5.71 by $0.32. The business had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in TMO. BlackRock Inc. bought a new stake in Thermo Fisher Scientific in the 2nd quarter worth approximately $15,501,867,000. Corient Private Wealth LP purchased a new stake in shares of Thermo Fisher Scientific during the 2nd quarter worth approximately $382,547,000. Bank of New York Mellon Corp bought a new position in shares of Thermo Fisher Scientific during the 2nd quarter valued at approximately $1,974,561,000. Bank of America Corp DE bought a new position in shares of Thermo Fisher Scientific during the 2nd quarter valued at approximately $1,952,930,000. Finally, Auto Owners Insurance Co grew its holdings in shares of Thermo Fisher Scientific by 57,845.0% in the fourth quarter. Auto Owners Insurance Co now owns 2,427,896 shares of the medical research company’s stock valued at $1,406,844,000 after purchasing an additional 2,423,706 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Insider Activity at Thermo Fisher Scientific

In other news, CAO Joseph Holmes sold 420 shares of the business’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $584.81, for a total value of $245,620.20. Following the transaction, the chief accounting officer owned 2,966 shares of the company’s stock, valued at approximately $1,734,546.46. The trade was a 12.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Lisa Britt sold 11,440 shares of the company’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the transaction, the vice president owned 14,784 shares of the company’s stock, valued at approximately $9,064,366.08. This represents a 43.62% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 73,768 shares of company stock worth $44,122,820. 0.33% of the stock is currently owned by corporate insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc is a global provider of laboratory products, analytical instruments, reagents, consumables, software and services. Its offerings support research, drug discovery and development, clinical diagnostics, biotechnology and pharmaceutical manufacturing, as well as environmental, industrial and other applied markets.

The company’s portfolio includes mass spectrometers, genetic analysis and sequencing systems, electron microscopes, chromatography equipment, laboratory plastics, cell culture products, antibodies, protein and molecular biology reagents, and diagnostic testing solutions.